Alector, Inc.
ALECHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAlector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. The $274.7M market capitalization puts ALEC squarely in micro-cap range for its industry. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Market Cap
$274.7M
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
-3.30
EPS (TTM)
$-1.09
EPS (Fwd)
$-0.75
ROE
-385.1%
ROA
-27.6%
Cash
$172.8M
Total Debt
$32.8M
Free CF
-$107.3M
52W Change
-10.9%
Annual Financials
Cash vs Debt
Where ALEC stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, ALEC finished 16.83% above its 150-day moving average ($2.02) and 25.53% above its 200-day moving average ($1.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALEC overbought or oversold?
At the August 26, 2026 close, ALEC's RSI(14) was 71.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $172.8M in cash and $32.8M in debt, ALEC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$107.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -385.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $207.1M (2021) to $21.0M (2025), a 90% decline worth watching.
With a beta below 0.7, Alector, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ALEC has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ALEC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.